The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
1 other identifier
observational
2
0 countries
N/A
Brief Summary
Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage. Whether EOS is a good predictor for in-hospital major adverse cardiac events (MACEs) of patients with ST-segment elevation myocardial infarction remains unknown. The aims of this study was to evaluate prognostic role of EOS for in-hospital MACEs in STEMI patients who have undergone primary percutaneous coronary intervention (PCI)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2015
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2018
CompletedFirst Submitted
Initial submission to the registry
November 7, 2018
CompletedFirst Posted
Study publicly available on registry
November 14, 2018
CompletedNovember 14, 2018
November 1, 2018
1.8 years
November 7, 2018
November 13, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
major adverse cardiac events
the relationship between reduced eosinophils percentage and in-hospital MACE
The median time of 7 days
Eligibility Criteria
STEMI Patients
You may qualify if:
- Patients with STEMI who underwent PCI within 12 hours from symptom onset
- Patients from whom informed consent has been properly obtained in writing prior to start of the trial.
You may not qualify if:
- Patients with previous myocardial infarction, congenital heart disease
- Patients with liver disease, and renal failure
- Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dongying Zhanglead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 7, 2018
First Posted
November 14, 2018
Study Start
October 1, 2015
Primary Completion
August 1, 2017
Study Completion
November 1, 2018
Last Updated
November 14, 2018
Record last verified: 2018-11